



**13<sup>th</sup> August, 2021**

**To  
The Secretary Listing Department  
BSE Limited  
Department of Corporate Services,  
Phiroz Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip Code: 512479**

Dear Sir/Madam,

**Sub: Intimation of the Outcome of Board Meeting.,  
Ref: Our Board Meeting Notice Dated 06<sup>th</sup> August, 2021  
Scrip Code: 512479**

.....

We wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. 13<sup>th</sup> of August, 2021 has inter alia approved Un-Audited Financial Results for the quarter ended 30<sup>th</sup> June, 2021.

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of statement of Un-Audited Financial Results for the quarter ended 30.06.2021 along with the limited review report issued by Statutory Auditors M/s. N G Rao & Associates, Chartered Accountants, enclosed for your records and necessary dissemination.

The Board Meeting commenced at 11.00 a.m and concluded at 11.35 a.m

Kindly acknowledge the receipt of this letter.

Yours truly,  
**For GAYATRI TISSUE & PAPERS LTD**



**DINESH VEMULA**  
Company Secretary & Compliance Officer

Regd. Office :

**Gayatri Tissue & Papers Limitd**  
16/ 137, No. 5, Near Prabodhan Krida Bhawan  
Siddhartha Nagar, Goregaon (west) MUMBAI 400 104

Email: [csdinesh@gayatri.co.in](mailto:csdinesh@gayatri.co.in); CIN: L45100MH1987PLC042141

**Corp Office:**  
B1, 6-3-1090, TSR Towers Raj Bhavan Road,  
Somajiguda, Hyderabad 500 082. A.P

**T** +91 40 2331 0330 / 4284 / 4296      [www.gayatri.co.in](http://www.gayatri.co.in)  
**F** +91 40 2339 8435



**Limited Review Report**

**To**  
**The Board of Directors**  
**M/s. Gayatri Tissue and Papers Limited.**

We have reviewed the accompanying statement of unaudited financial results of M/s. Gayatri Tissue and Papers Limited for the period ended 30.06.2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N G Rao & Associates**  
Chartered Accountants  
Firm's Registration Number: 009399S

**(G. Nageswara Rao)**  
Partner  
Membership No.207300

Place: Hyderabad  
Date: 13.08.2021  
UDIN: 21207300AAABJS5032



## GAYATRI TISSUE & PAPERS LIMITED

Regd. Office:16/137 Siddharthanagar,Road No.5,Near Prabodhan Krida Bhavan, Goregaon(West) , MUMBAI-400 104

UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021

CIN: L45100MH1987PLC042141

Rs. In Lakhs

S.No.	Particulars	Quarter ended	Preceding	Quarter	Year Ended
		30.06.2021	quarter	ended	31.03.2021
		Un Audited	Audited	Un Audited	Audited
1	<b>InCome from Operations</b>				
	(a) Revenue from operations	10.01	5.03	10.06	34.79
	(b) Other Income	-	0.07	-	0.07
	<b>Total Revenue (1)</b>	<b>10.01</b>	<b>5.10</b>	<b>10.06</b>	<b>34.86</b>
2	<b>Expenses:</b>				
	(a) Cost of Materials Consumed	-	-	-	5.02
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Change in Inventories of finished goods, work-in-progress and stock-in-trade	1.50	(2.50)	2.50	2.83
	(d) Employees benefits expense	3.16	3.15	3.16	12.62
	(e) Finance costs	-	-	-	-
	(f) Depreciation and amortisation expenses	-	-	-	-
	(g) Manufacturing expenses	-	-	-	-
	(h) Research & Development expenses	-	-	-	-
	(i) Other Expenses	4.75	2.99	4.07	11.07
	<b>Total Expenses (2)</b>	<b>9.41</b>	<b>3.64</b>	<b>9.73</b>	<b>31.54</b>
3	<b>Profit /Loss before exceptional and extraordinary items and tax (1-2)</b>	<b>0.60</b>	<b>1.46</b>	<b>0.33</b>	<b>3.32</b>
4	Exceptional Items	-	-	-	-
5	<b>Profit before extraordinary items and tax (3-4)</b>	<b>0.60</b>	<b>1.46</b>	<b>0.33</b>	<b>3.32</b>
6	Extraordinary Items	-	-	-	-
7	<b>Profit before tax (5-6)</b>	<b>0.60</b>	<b>1.46</b>	<b>0.33</b>	<b>3.32</b>
8	<b>Tax Expenses:</b>				
	(1). Current tax	0.16	0.37	0.09	0.86
	(2). Deferred tax	-	-	-	-
9	<b>Profit (Loss) for the period from continuing operations (7-8)</b>	<b>0.44</b>	<b>1.09</b>	<b>0.24</b>	<b>2.46</b>
10	Profit / Loss from discontinuing operations	-	-	-	-
11	Tax expenses of discontinuing operations	-	-	-	-
12	<b>Profit/Loss from discontinuing operations (after tax) (10-11)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
13	<b>Profit (Loss) for the period (9+12)</b>	<b>0.44</b>	<b>1.09</b>	<b>0.24</b>	<b>2.46</b>
14	<b>Other Comprehensive Income</b>				
	A (1). Items that will not be reclassified to profit or loss	-	-	-	-
	(2). Incometax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (1). Items that will be reclassified to profit or loss	-	-	-	-
	(2). Incometax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total other Comprehensive Income (A+B)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>0.44</b>	<b>1.09</b>	<b>0.24</b>	<b>2.46</b>
	<b>(comprising Profit/Loss) and other comprehensive income for the period</b>				
16	<b>Paid Up Equity Capital (Face value of Rs.10/- each)</b>	150.00	150.00	150.00	150.00
17	<b>Reserves</b>				268.04
18	<b>Earning Per Equity Share (EPS):</b>				
	Basic and Diluted	<b>0.03</b>	<b>0.07</b>	<b>0.02</b>	<b>0.16</b>

**Notes:**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 13th August, 2021 and the statutory auditors of the company have carried out limited review of the same.
- 2 The Company is not having any Subsidiary, Joint Ventrue and Associate, hence no consolidated results are published.
- 3 The company does not have more than one reportable segment. Accordingly, pursuant to (IND AS 108) on segment reporting issued by the Institute of Chartered Accountants of India, segment information is not required to be provided.
- 4 There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor compalints during the quarter.
- 5 Previous year / quarter figures have been re-grouped and recasted wherever necessary.

Place: Hyderabad.  
Date: 13.08.2021



(P. MARUTHI BABU)  
Executive Director